Markets
CorMedix Stock Soars 11% After Management Forecasts Higher Reimbursement Payments
Shares entered Monday down 60% for the year, while the company has suspended its 2027 DefenCath sales outlook.
CorMedix (CRMD) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Markets
Shares entered Monday down 60% for the year, while the company has suspended its 2027 DefenCath sales outlook.
Earnings
Customer pricing and Medicare Advantage talks remain unfinished, while the company narrowed its 2026 adjusted earnings outlook.
Earnings
Medicare payments will reset quarterly in 2027, complicating pricing even as management expects reimbursement above the current rate.
SEC Filings
CorMedix suspended its 2027 DefenCath sales outlook while keeping its 2026 revenue forecast at $325 million to $345 million.
SEC Filings
The pending injectable is excluded from 2027 guidance, and CorMedix retained $75 million of borrowing capacity for future deals.
SEC Filings
Management expects $45 million–$60 million in annual savings by year-end 2027 as it adds four drugs to its hospital sales platform.
SEC Filings
The company reaffirmed 2026 revenue guidance of $325 million to $345 million and reported about $355 million in cash.
Earnings
CorMedix says the FDA accepted the filing and set a first-quarter 2027 target action date, with promotion aimed at the second half of 2027.